Board of Directors
James Corbett, Chief Executive Officer, Vertos Medical 
Mr. Corbett joined Vertos Medical in November 2008 as President, Chief Executive Officer and Member of the Board of Directors. From 2001 to 2008, Mr. Corbett served as CEO and President of ev3, Inc., and was Chairman of the Board of Directors from 2007 to 2008. Mr. Corbett served as Chairman of the Board of Micro Therapeutics, Inc., from 2002 to 2005, prior to its merger with ev3. From 1999 to 2001, Mr. Corbett was President and CEO of Home Diagnostics, Inc. From 1992 to 1998, Mr. Corbett served as the President of Boston Scientific International. This included the Scimed / Boston Scientific acquisition. Mr. Corbett was General Manager of Baxter Cardiovascular, Japan from 1989 to 1992, and held various sales and marketing positions at Baxter Healthcare Corporation from 1981 to 1992.
Mr. Corbett has been a board member of several public and private companies including Symphonix (1999-2001), Therox (2000-2003), Alsius (2003-2004) and ev3 (2001-2008). Mr. Corbett holds a B.S. in Business Administration from Kansas University.
Andrew Firlik, MD, General Partner, Foundation Medical Partners
Dr. Firlik has served as a Vertos Medical director since 2008. He became a General Partner of Foundation Medical Partners in 2005, concentrating on medical device and biopharmaceutical investments. Prior to Foundation, he was a venture partner at Sprout Group and a managing director of its healthcare technology spinout, New Leaf Venture Partners. Previously, he was a principal at Canaan Partners. Dr. Firlik has led numerous venture capital investments and has served as a founder, founding investor, or director of many companies, including Northstar Neuroscience, NeuroVista, Sopherion Therapeutics, Transoma, Omnisonics, Marinus Pharmaceuticals, Viacor, and Spine Wave.
Dr. Firlik currently serves as the Chairman of Intelect Medical, a neuromodulation company, and recently served as Chairman of NovaVision, a medical therapeutics firm focusing on neuroplasticity for visual disorders. His additional current or recent board seats include BridgePoint Medical, Clear Catheter Solutions, NeuroVista, SetPoint Medical, Spine Wave, and Visiogen. Dr. Firlik studied biology at Cornell University and Oxford University, received his MBA from the Katz Graduate School of Business at the University of Pittsburgh, and his M.D. from Cornell University Medical College. Dr. Firlik is a board certified neurosurgeon and has published numerous scientific articles in the field.
Myles Greenberg, MD, Partner, CHL Medical Partners
Dr. Greenberg has served as a Vertos Medical director since 2008. He is a Partner of CHL Medical Partners, focusing on the biotechnology, medical device and healthcare services sectors. Prior to joining CHL Medical Partners in 2004, Dr. Greenberg was a Senior Principal at A.M. Pappas & Associates where he led a number of investments including Angiomics (acquired by PDL BioPharma), FlowCardia, LipoScience, NuVasive (Nasdaq: NUVA), and Syntonix (acquired by Biogen Idec).
Dr. Greenberg's current board positions in addition to Vertos include Millennium Pharmacy Systems, Oriel Therapeutics, ParinGenix, and Still River Systems,. He is a graduate of the University of Pennsylvania School of Engineering and Applied Science, Yale University School of Medicine and Harvard Business School and is a diplomate of the American Board of Emergency Medicine.
Daniel Pelak, Senior Advisor, Welsh, Carson, Anderson & Stowe
Mr. Pelak has served as a Vertos Medical director since 2008. He is a Senior Advisor with Welsh, Carson, Anderson & Stowe ("WCAS"), focusing on investments in the healthcare industry. Prior to joining WCAS, Mr. Pelak was the Chief Executive Officer at InnerPulse, a privately held, early-stage cardiac medical device company. Prior to joining InnerPulse, he was the Chief Executive Officer of Closure Medical Corporation, a publically traded biomaterial-based medical adhesive company, until its acquisition by Johnson & Johnson in 2005. Mr. Pelak began his industry career at Medtronic, where he spent over 20 years. His executive assignments at Medtronic included Vice President of US Marketing, and worldwide responsibility for three different operating divisions as Vice President and General Manager.
Mr. Pelak's current or recent board positions are InnerPulse, Inc., AGA Medical Corp., Affinergy, Inc., Mardil, Inc. Oncoscope, Inc. Mr. Pelak is a graduate of Penn State University with a B.S. in Biology.
Harry Ross, MD, Managing Partner, Aweida Venture Partners
Dr. Ross has been a Director of Vertos since 2005. He currently is a Managing Partner at Aweida Ventures in charge of Life Science Investments. Dr. Ross previously held the role of CEO/Chairman of RxKinetix.
Current or recent director positions include Illumitex, Body Beam Research, Intela Interventional, Interferometrics, Permacharge, NetHesive, MedWired. He received his Medical Degree from Oregon Health Sciences University with post graduate training in General Surgery and Emergency Medicine at Hennepin County Medical Center holding current Board Certification in Emergency Medicine.
John F. Ryan, Partner, ONSET Ventures
Mr. Ryan has served as a director of Vertos Medical since 2009. He joined ONSET Ventures in 2008 after focusing throughout his career on the founding, building and financing of companies across many sectors of the healthcare industry, at stages ranging from early company formation to large industry leaders.
Prior to ONSET, Mr. Ryan led the venture-investing efforts in the medical device sector for Panorama Capital, JPMorgan Partners, and Chase Capital Partners. During that time he led investments in and served on the board of directors of companies such as CardioKinetix, FlowCardia, Novasys Medical and PowerVision. Previously Mr. Ryan worked with Morgan Stanley Venture Partners where he participated in investments in companies such as Intuitive Surgical (NASDAQ: ISRG), R2 Technologies (acquired by Hologic), and Rita Medical Systems (acquired by AngioDynamics). Mr. Ryan has also worked with Morgan Stanley's investment banking group as part of a team that was a global leader in M&A and business financing for health care companies.
At ONSET Ventures, Mr. Ryan focuses on helping to create or invest in companies in the medical technology and health care IT sectors. Mr. Ryan serves as a board member or board observer for Novasys Medical, Valeritas and Vertos Medical.
Mr. Ryan holds an MBA from Harvard Business School as well as a Bachelor of Science degree with high honors from the University of Colorado. Mr. Ryan also serves on the board of directors of Mills-Peninsula Health Services hospital organization and on the medical device screening committee for the Life Science Angels investment group.
Dan Watkins, PhD, Managing Director, DFJ Mercury
Dr. Watkins has served as a director of Vertos Medical since 2005. He has been Managing Director of DFJ Mercury since 2005. Prior to co-founding DFJ Mercury, Dr. Watkins was the founder and Managing Partner of A3 Associates, L.P., a Houston-based investment firm focused on seed-stage investments in university based start-up companies. In this capacity, he co-founded both Nanospectra Biosciences, Inc. and X-EMI, Inc. Prior to A3 Associates, Dr. Watkins had 8 years of experience in management and technical roles technology companies.
Dr. Watkins' current board positions include DNAtriX, Illumitex, GlycosBio, Imagnx and Marval Biosciences. He received his B.S. in Materials Science and Engineering from Rice University, and his M.S. and Ph.D. in Materials Science and Engineering from Carnegie Mellon University.
